Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas

Cancer Immunology, Immunotherapy

Volumn 62, Issue 4, 2013, Pages 629-637

  Baghdadi, Muhammad ^a,c   Nagao, Hiroko ^a   Yoshiyama, Hironori ^a   Akiba, Hisaya ^b   Yagita, Hideo ^b   Dosaka Akita, Hirotoshi ^c   Jinushi, Masahisa ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer vaccines; CD8+ T cells; Melanoma; NK cells; TIM 3; TIM 4

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGIC FACTORS AND AGENTS ACTING ON THE IMMUNE SYSTEM; CANCER VACCINE; FLT3 LIGAND VACCINE; MONOCLONAL ANTIBODY; T CELL IMMUNOGLOBULIN MUCIN PROTEIN 3; T CELL IMMUNOGLOBULIN MUCIN PROTEIN 3 MONOCLONAL ANTIBODY; T CELL IMMUNOGLOBULIN MUCIN PROTEIN 4; T CELL IMMUNOGLOBULIN MUCIN PROTEIN 4 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG TARGETING; FEMALE; MELANOMA; MELANOMA CELL; MONOTHERAPY; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DRUG SYNERGISM; FEMALE; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; RECEPTORS, VIRUS; TUMOR MICROENVIRONMENT;

EID: 84877817118     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1371-9     Document Type: Article

References (33)

1. Dougan M, Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27:83-117
2. Andrews DM, Maraskovsky E, Smyth MJ (2008) Cancer vaccines for established cancer: how to make them better? Immunol Rev 222:242-255
3. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296
4. Drake CG, Jaffee E, Pardoll DM (2006) Mechanisms of immune evasion by tumors. Adv Immunol 90:51-81
5. Peggs KS, Segal NH, Allison JP (2007) Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell 12:192-199
6. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-264
7. Peggs KS, Quezada SA, Allison JP (2008) Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 224:141-165
8. Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24:207-212
9. Woo S-R, Turnis ME, Goldberg MV et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72:917-927
10. Fourcade J, Sun Z, Pagliano O et al (2012) CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 72:887-896
11. Fourcade J, Sun Z, Benallaoua M et al (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207:2175-2186
12. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC (2012) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207:2187-2194
13. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723
14. Brahmer JR, Tykodi SS, Chow LQM et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465
15. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-5244
16. Ngiow SF, Teng MW, Smyth MJ (2011) Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 71:6567-6571
17. Anderson AC (2012) Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 24:213-216
18. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S (2007) Identification of Tim4 as a phosphatidylserine receptor. Nature 450:435-439
19. Kobayashi N, Karisola P, Peña-Cruz V et al (2007) TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 27:927-940
20. Rodriguez-Manzanet R, Sanjuan MA, Wu HY et al (2010) T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc Natl Acad Sci USA 107:8706-8711
21. Jinushi M, Sato M, Kanamoto A et al (2009) Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms. J Exp Med 206:1317-1326
22. Curran MA, Allison JP (2009) Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res 69:7747-7755
23. Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107:4275-4280
24. Nakayama M, Akiba H, Takeda K et al (2009) Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113:3821-3830
25. Smyth MJ, Hayakawa Y, Takeda K, Yagita H (2002) New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2:850-861
26. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565-1570
27. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MWL, Smyth MJ (2011) Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res 71:3540-3551
28. Chiba S, Baghdadi M, Akiba H et al (2012) Tumor-infiltrating dendritic cells suppress nucleic acids-mediated innate immune response through TIM-3-HMGB1 interactions. Nat Immunol 13:832-842
29. Qian B-Z, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39-51
30. Shiao SL, Ganesan AP, Rugo HS, Coussens LM (2011) Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 25:2272-2559
31. Iwasaki A, Medzhitov R (2010) Regulation of adaptive immunity by the innate immune system. Science 327:291-295
32. Jinushi M (2012) The role of innate immune signals in antitumor immunity. Oncoimmunology 1:189-194
33. Green DR, Ferguson T, Zitvogel L, Kroemer G (2009) Immunogenic and tolerogenic cell death. Nat Rev Immunol 9:353-363